{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-002846","form_type":"8-K","ticker":"NTRA","cik":"0001604821","company_name":"Natera, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.166853+00:00","generated_at":"2026-05-28T03:22:27.119425+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Natera FY2024 preliminary revenue ~$1.7B (+56% YoY), positive cash inflow $86.3M","bullets":["Q4 2024 revenue ~$472M (+52% YoY); FY2024 revenue ~$1.7B (+56% YoY), ~$53M above top end of guidance.","Positive non-GAAP cash inflow of $86.3M in FY2024 vs. outflow of $267.1M in FY2023.","Total tests processed in FY2024 ~3.06M (+22.8% YoY); Q4 oncology tests up 54.7% to ~150,800.","Clinical oncology tests in FY2024 ~498,300 (+63% YoY); Q4 sequential increase of ~14,800 tests.","Company to present additional updates at J.P. Morgan Healthcare Conference on Jan 15, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-002846","json":"https://secwatch.observer/filing/0001104659-25-002846.json","markdown":"https://secwatch.observer/filing/0001104659-25-002846.md","text":"https://secwatch.observer/filing/0001104659-25-002846.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604821/000110465925002846/0001104659-25-002846-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604821/000110465925002846/tm253044d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:22:27.119425+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}